CN102072960A - Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample - Google Patents
Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample Download PDFInfo
- Publication number
- CN102072960A CN102072960A CN 201010136227 CN201010136227A CN102072960A CN 102072960 A CN102072960 A CN 102072960A CN 201010136227 CN201010136227 CN 201010136227 CN 201010136227 A CN201010136227 A CN 201010136227A CN 102072960 A CN102072960 A CN 102072960A
- Authority
- CN
- China
- Prior art keywords
- ngal
- sample
- antibody
- people
- elisa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to a method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in a sample. The method comprises the following steps of: reacting an antibody of the NGAL with human NGAL of a specimen to be detected to form a compound which causes turbidity change; characterizing the change by using light projection intensity or light scattering intensity; and finding out the content of the human NGAL in the specimen to be detected from the concentration of the NGAL standard product and a standard curve of corresponding light scattering intensity or light transmission intensity. The method has the advantages of high sensitivity, high recovery rate and good repeatability, and a detection measure having the advantages of simplicity, convenience, good repeatability, strong adaptability and high speed is determined for measuring the NGAL in the samples of urine or blood plasma, and the like.
Description
Technical field
The present invention relates to the detection method of neutrophil gelatinase-associated lipocalin in a kind of sample.
Background technology
Neutrophil gelatinase-associated lipocalin (be called for short NGAL) be 1993 at first found in neutrophil leucocyte, relevant with processes such as the generation of inflammation, embryonic development, immune response, chemotaxis, signal transduction and kinds of tumors and development.Domestic and international research shows in recent years, and NGAL albumen is sent out the characteristics that have specific expressed variation in the process in multiple disease, makes NGAL become the biomarker that detects disease.
In ischemic and toxicity injury of kidney process take place, the NGAL in the renal cells will significantly increase, and in two hours of beginning, the NGAL level will significantly increase in urine and the blood, so NGAL is the responsive mark of early stage acute injury of kidney.
Acute renal damage prognosis will develop into acute renal failure.General diagnostic method is as measuring serum creatinine or cysteine proteinase inhibitor C (Cystatin C), can only damage one day after very the person detect in several days.There are some researches show, NGAL content detection distribution of results 0.7-9.6ng/ml in healthy volunteer's urine, mean value is 5.3ng/ml.And the content detection result in the blood plasma is 37-106ng/ml, and mean value is 63ng/ml.Behind injury of kidney, with the machine testing severe case, the concentration of urine NGAL is that 110ng/ml does not wait to 40000ng/ml.And their EDTA anticoagulate plasma testing result is that 25ng/ml is to 3491ng/ml.Judge that according to 90% positive predictive value that the acute renal failure patient detects the positive judgment value of NGAL is 350ng/ml in the urine, and the positive judgment value that blood plasma detects is 400ng/ml.
Homology analysis shows, (neu-related lipocalin NRL) has very high homology for NGAL and the 24p3 of mouse and the relevant lipocalin of neu of rat.The 24p3 of mouse is synthetic in liver, raises during inflammatory reaction, and 24p3 also sees macrophage and endometrium in addition, especially the endometrium in reproduction period.With steroid hormone the 24p3 level in the respective organization is raise, and some growth factors and tumour promote that the factor also can make its rising.Monkey poison SV40, polyoma poison or other malicious infection can stimulate the expression of the mouse kidney cell 24p3mRNA of cultivation to increase 7-10 doubly.And raise along with the synthetic increase of large T antigen.Therefore 24p3 is considered to oncoprotein.This shows that simultaneously NGAL may be human a kind of new oncogene.
The expression that experiment showed, the NGAL in ovarian cancer cell line, colon tumor and breast cancer etc. obviously strengthens.The NGAL strong positive of SABC proof in cancerous lung tissue, and BAC cancer and carcinoma muco-cellulare dyeing are the strongest, NGAL can be increased to strong positive from feminine gender in cancer of pancreas.
In sum, set up at the method for quick of NGAL in the sample and will provide a strong tool for the research of this albumen.
Summary of the invention
The invention provides the described method of method that detects NGAL in the sample and comprise following steps:
I) use related equipment to collect serum, blood plasma and urine that sample comprises the people,
Ii) sample and antibody contact reaction,
Iii) detect the concentration of NGAL in the sample.
Preferably measure the NGAL level by immuno-chemical method, the example of this method comprises but never is limited to immunoturbidimetry, sandwich method ELISA, competition law ELISA.
To biological specimen, can carry out with any method of satisfied analysis specificity, sensitivity and degree of accuracy that provides.In the test experience, use monoclonal, polyclonal antibody or any molecule that can combine of NGAL with the NGAL specificity.The binding molecule at first NGAL that catches in the sample of immobilization forms compound, and the detectable binding molecule of another one mark is again in conjunction with above-mentioned compound, thereby the value indirect reaction that demonstrates the compound amount by ad hoc approach at last goes out the content of NGAL in the sample.Can directly utilize antibody that free NGAL antibody or coupling latex particle exist with colloidal form and NGAL in the sample directly to combine formed compound in addition and cause that turbidity changes; Use up projection intensity or light scattering intensity and characterize this variation; Find the content of the people NGAL of sample to be checked from the typical curve of the concentration of people NGAL standard items and corresponding light scattering strength or transmittance intensity;
Description of drawings
Fig. 1 is that sandwich method ELISA detects recombined human NGAL canonical plotting;
Fig. 2 is that competition law ELISA detects recombined human NGAL canonical plotting.
Embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1 latex enhance immunity turbidimetry detects the NGAL content in the human urine
Realize the technical scheme of this example: the immunoturbidimetry of a kind of people of detection NGAL, at first crosslinked with latex with the polyclonal antibody of anti-NGAL, with the NGAL reaction of latex solution after crosslinked and sample to be checked, formed compound causes that turbidity changes then; Use up projection intensity or light scattering intensity and characterize this variation; Find the NGAL content of sample to be checked from the typical curve of the concentration of NGAL standard items and corresponding light scattering strength or light projection intensity; The polyclonal antibody of wherein used NGAL is tired and is at least 1: 500, does not contain assorted antibody, has many kinds of antigenic determinants of identification NGAL; Sample to be checked does 1 with thinning agent: 200-1: 1000 dilutions;
In the said method, described NGAL standard items are pure NGAL, and its concentration is 0.2mg/ml, do 1: 200 times of dilution with thinning agent earlier, do doubling dilution again, make the series standard product, are made for typical curve and use;
Embodiment 2 usefulness sandwich method ELISAs are determined human urine NGAL concentration
Concrete steps are: bag is by the NGAL antibody A; Prepare serial NGAL standard items; Prepare human urine; The human urine of series standard product or required value is added in the 96 micropore plate holes, make again mark, binding site is different from the antibody B combination that is coated on antibody A on 96 microwell plates, with matrix liquid colour developing color development stopping after 20-30 minute, measure the reacted absorbance of NGAL in above-mentioned series standard product and the human urine to be detected after 10 minutes; Set up the typical curve of the concentration of series standard product and absorbance and from curve, find the concentration of NGAL of the human urine of required value.
Embodiment 3 usefulness competition law ELISA determine human urine NGAL concentration
Concrete steps are: bag is by the NGAL polyclonal antibody; Prepare serial NGAL standard items; Prepare human urine; Make the human urine of series standard product or required value and the NGAL standard items mixing of mark; With matrix liquid colour developing color development stopping after 20-30 minute, measure the reacted absorbance of NGAL in above-mentioned series standard product and the human urine to be detected after 10 minutes; Set up the typical curve of the concentration of series standard product and absorbance and from curve, find the concentration of NGAL of the human urine of required value.
Claims (12)
1. the detection method of neutrophil gelatinase-associated lipocalin in the sample.
2. method according to claim 1, it is characterized in that, be based upon on the antigen and antibody specific reaction principle basis, by the concentration of the relevant lipocalin protein (NGAL) of human neutrophil gelatinase in the immunological method test sample that includes but not limited to immunoturbidimetry and enzyme linked immunological (ELISA) method.
3. method according to claim 1 is characterized in that, comprises the steps:
I) use related equipment to collect sample and comprise serum, blood plasma and urine,
Ii) NGAL in the sample and antibody contact reaction,
Iii) detect the concentration of people NGAL in the sample.
4. sample according to claim 2 is characterized in that including but not limited to people's urine, blood plasma and serum.
5. antibody according to claim 3 is characterized in that this antibody is polyclonal antibody or the monoclonal antibody by the people NGAL immune animal acquisition of natural or reorganization.
6. immunoturbidimetry according to claim 2 is characterized in that: with the antibody of anti-people NGAL, with the people NGAL reaction of sample to be checked, formed compound causes that turbidity changes; Use up projection intensity or light scattering intensity and characterize this variation; Find the content of the people NGAL of sample to be checked from the typical curve of the concentration of people NGAL standard items and corresponding light scattering strength or transmittance intensity.
7. enzyme linked immunological according to claim 2 (ELISA) method is characterized in that: comprise double antibodies sandwich method ELISA, competition law ELISA.
8. enzyme linked immunological according to claim 2 (ELISA) method, it is characterized in that: people NGAL is immobilization in advance, or people NGAL antibody immobilization in advance.
9. enzyme linked immunological according to claim 2 (ELISA) method is characterized in that: the scope that detects NGAL content is: 7.8ng/ml-500ng/ml.
10. competition law according to claim 7 is if direct competition method is characterized in that: immobilization people NGAL antibody in advance.
11. competition law according to claim 7 is if the indirect competition method is characterized in that: immobilization people NGAL in advance.
12. immobilization according to claim 8, it is characterized in that: with people NGAL or people NGAL antibody sandwich to solid support, this holder can be, the polystyrene or the polyvinyl chloride surface that for example are used for enzyme linked immunosorbent assay, or latex (polystyrene) particle, or by the filter glass rod formed of polyethylene particle of compression, or porous digest cellulose matrix, or in fact be any suitable holder in the immunochemical analyses use.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010136227 CN102072960A (en) | 2010-03-29 | 2010-03-29 | Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010136227 CN102072960A (en) | 2010-03-29 | 2010-03-29 | Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102072960A true CN102072960A (en) | 2011-05-25 |
Family
ID=44031580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010136227 Pending CN102072960A (en) | 2010-03-29 | 2010-03-29 | Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102072960A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102662064A (en) * | 2012-04-26 | 2012-09-12 | 苏州照康生物技术有限公司 | Immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and preparation method thereof |
CN102680698A (en) * | 2011-07-29 | 2012-09-19 | 南京诺尔曼生物技术有限公司 | Neutrophil gelatinase-associated lipocalin (NGAL) assay kit (latex-enhanced immunoturbidimetry) |
CN102775473A (en) * | 2012-07-30 | 2012-11-14 | 重庆业为基生物科技有限公司 | B cell epitope peptide of human neutrophil gelatinase associated lipocalin and application thereof |
CN102967714A (en) * | 2012-12-10 | 2013-03-13 | 天津市协和医药科技集团有限公司 | Neutrophil gelatinase associated lipocalin (NGAL) chemiluminescence detection kit |
CN103048464A (en) * | 2012-10-17 | 2013-04-17 | 武汉生之源生物科技有限公司 | Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof |
WO2013097606A1 (en) * | 2011-12-30 | 2013-07-04 | 北京九强生物技术股份有限公司 | Assay kit for neutrophil gelatinase-associated lipocalin |
CN104198732A (en) * | 2014-08-28 | 2014-12-10 | 宁波瑞源生物科技有限公司 | Kit for detecting content of neutrophil gelatinase-associated lipocalin (NGAL) |
CN104313157A (en) * | 2014-10-27 | 2015-01-28 | 东南大学 | Method for detecting NGAL with proximity ligation technology |
WO2018076284A1 (en) * | 2016-10-28 | 2018-05-03 | The University Of Hong Kong | Non-polyaminated lcn2 as a biomarker for diagnosis and treatment of cardiometabolic diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1791797A (en) * | 2003-03-27 | 2006-06-21 | 儿童医院医疗中心 | A method and kit for detecting the early onset of renal tubular cell injury |
CN101027556A (en) * | 2004-06-07 | 2007-08-29 | 儿童医院医疗中心 | Method for the early detection of renal disease and injury |
CN101163971A (en) * | 2004-12-20 | 2008-04-16 | 免疫体公司 | Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders |
WO2008061149A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
CN101421622A (en) * | 2006-02-17 | 2009-04-29 | 儿童医学中心公司 | Free NGAL as a biomarker for cancer |
CN101566633A (en) * | 2009-04-17 | 2009-10-28 | 武汉华美生物工程有限公司 | Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity |
-
2010
- 2010-03-29 CN CN 201010136227 patent/CN102072960A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1791797A (en) * | 2003-03-27 | 2006-06-21 | 儿童医院医疗中心 | A method and kit for detecting the early onset of renal tubular cell injury |
CN101027556A (en) * | 2004-06-07 | 2007-08-29 | 儿童医院医疗中心 | Method for the early detection of renal disease and injury |
CN101163971A (en) * | 2004-12-20 | 2008-04-16 | 免疫体公司 | Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders |
CN101421622A (en) * | 2006-02-17 | 2009-04-29 | 儿童医学中心公司 | Free NGAL as a biomarker for cancer |
WO2008061149A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
CN101566633A (en) * | 2009-04-17 | 2009-10-28 | 武汉华美生物工程有限公司 | Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102680698B (en) * | 2011-07-29 | 2016-03-30 | 南京诺尔曼生物技术有限公司 | Neutrophil gelatinase-associated lipocalin (NGAL) measures kit (latex enhancing immune turbidimetry) |
CN102680698A (en) * | 2011-07-29 | 2012-09-19 | 南京诺尔曼生物技术有限公司 | Neutrophil gelatinase-associated lipocalin (NGAL) assay kit (latex-enhanced immunoturbidimetry) |
WO2013097606A1 (en) * | 2011-12-30 | 2013-07-04 | 北京九强生物技术股份有限公司 | Assay kit for neutrophil gelatinase-associated lipocalin |
CN102662064A (en) * | 2012-04-26 | 2012-09-12 | 苏州照康生物技术有限公司 | Immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and preparation method thereof |
CN102775473A (en) * | 2012-07-30 | 2012-11-14 | 重庆业为基生物科技有限公司 | B cell epitope peptide of human neutrophil gelatinase associated lipocalin and application thereof |
CN102775473B (en) * | 2012-07-30 | 2018-10-12 | 重庆业为基生物科技有限公司 | The B cell epitope peptide fragment of human neutrophil gelatinase-associated lipocalin and its application |
CN103048464A (en) * | 2012-10-17 | 2013-04-17 | 武汉生之源生物科技有限公司 | Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof |
CN103048464B (en) * | 2012-10-17 | 2015-04-15 | 武汉生之源生物科技有限公司 | Neutrophile granulocyte gelatinase related lipid transport protein detection kit and preparation method thereof |
CN102967714A (en) * | 2012-12-10 | 2013-03-13 | 天津市协和医药科技集团有限公司 | Neutrophil gelatinase associated lipocalin (NGAL) chemiluminescence detection kit |
CN104198732A (en) * | 2014-08-28 | 2014-12-10 | 宁波瑞源生物科技有限公司 | Kit for detecting content of neutrophil gelatinase-associated lipocalin (NGAL) |
CN104198732B (en) * | 2014-08-28 | 2015-08-19 | 宁波瑞源生物科技有限公司 | A kind of neutrophil gelatinase-associated lipocalin reagent box for detecting content |
CN104313157A (en) * | 2014-10-27 | 2015-01-28 | 东南大学 | Method for detecting NGAL with proximity ligation technology |
WO2018076284A1 (en) * | 2016-10-28 | 2018-05-03 | The University Of Hong Kong | Non-polyaminated lcn2 as a biomarker for diagnosis and treatment of cardiometabolic diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102072960A (en) | Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample | |
WO2017107974A1 (en) | Detection test kit for serum psmd4 proteins and detection method and application thereof | |
JP6096813B2 (en) | Multi-biomarker set for breast cancer diagnosis, detection method thereof, and breast cancer diagnosis kit including antibody thereto | |
CN101566633A (en) | Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity | |
CN104374919A (en) | Method for measurement of glycoprotein, reagent and sugar chain marker | |
CN101377492A (en) | Bladder chalone C determining reagent kit | |
CN102507918B (en) | Kit for determining anti-cyclic citrullinated peptide (Anti-CCP) antibody | |
CN105572353B (en) | A kind of antibody chip kit for detecting liver cancer marker | |
Liu et al. | Methodological evaluation and comparison of five urinary albumin measurements | |
US7081347B2 (en) | Method for predicting cardiovascular events | |
CN114200132B (en) | Kit for detecting thyroglobulin antibody and subtype thereof | |
US20120252040A1 (en) | Kit for diagnosing prostate cancer and diagnosis method | |
Chin et al. | Dual-enhanced plasmonic biosensing for point-of-care sepsis detection | |
Lund et al. | Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples | |
CN112166323A (en) | Direct immunoassay measurement of autoantibodies | |
CN108463724B (en) | Method for determining cancer, device for determining cancer, and computer program | |
KR102172016B1 (en) | A method for detection of CYFRA21-1 Autoantibody-Antigen complex , CYFRA21-1 antigen and Lung Cancer diagnosis kit by using ratio of these markers | |
JP2010091308A (en) | Method for diagnosing prostate carcinoma by lectin absorbing method and prostate carcinoma determining kit | |
CN206638678U (en) | Multi objective time-resolved fluoroimmunoassay for postoperative patient monitoring chromatographs kit | |
JP2019053068A (en) | Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors | |
CN108802400B (en) | Method for detecting compound IgA 1-alpha 1MG and kit for non-invasive detection of renal tissue injury | |
AU781669B2 (en) | Detection of prostate cancer measuring PSA/IGF-1 ratio | |
EP3879270A1 (en) | Method for detecting viral liver cancer | |
US11242408B2 (en) | Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis | |
KR101547058B1 (en) | Microsphere bead and Method for determination of protein using microsphere bead |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Wuhan Life Origin Biotech Co., Ltd. Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110525 |